董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Michael F. Mahoney CEO, Chairman of the Board 60 2142.08万美元 362.84 2025-12-01
Yoshiaki Fujimori Independent Director 73 35.17万美元 3.96 2025-12-01
Jessica L. Mega Independent Director 50 33.64万美元 0.62 2025-12-01
Susan E. Morano Independent Director 60 33.64万美元 0.79 2025-12-01
Ellen M. Zane Independent Director 73 35.67万美元 3.49 2025-12-01
Edward J. Ludwig Independent Director 73 37.67万美元 6.88 2025-12-01
John E. Sununu Independent Director 60 35.67万美元 13.44 2025-12-01
David S. Wichmann Independent Director 62 36.17万美元 4.59 2025-12-01
Cheryl Pegus Director 60 29.25万美元 0.32 2025-12-01
David C. Habiger Director 56 21.51万美元 0.35 2025-12-01

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Michael F. Mahoney CEO, Chairman of the Board 60 2142.08万美元 362.84 2025-12-01
John B. Sorenson Executive Vice President,Global Operations 57 未披露 未持股 2025-12-01
Eric Thepaut Executive Vice President and President, Europe,Middle East and Africa 63 未披露 未持股 2025-12-01
Arthur C. Butcher Executive Vice President and Group President,Med Surg and Asia Pacific 54 501.34万美元 24.58 2025-12-01
Vance R. Brown Senior Vice President,General Counsel,Corporate Secretary 55 未披露 未持股 2025-12-01
Jonathan Monson Executive Vice President and Chief Financial Officer 51 未披露 未持股 2025-12-01
Joseph M. Fitzgerald Executive Vice President and Group President,Cardiology 61 633.58万美元 90.16 2025-12-01
Wendy Carruthers Executive Vice President,Human Resources 56 未披露 未持股 2025-12-01

董事简历

中英对照 |  中文 |  英文
Michael F. Mahoney

Michael F. Mahoney,自2012年11月起担任总裁、首席执行官兼董事。他是波士顿科学国际有限公司的董事长、总裁兼首席执行官,自2023年11月起担任CVS Health Corporation董事。2011年10月17日起直到其现任职位期间,他担任公司总裁。作为公司的董事长,他专门负责心脏节律管理业务和内镜企业业务,以及某些固定企业要求。在加入该公司前, 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席,负责监督50000名员工和专营七家公司。2007年4月至2011年1月,Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长,负责骨科和神经科学业务。2001年1月至2007年3月,Mahoney先生担任全球医疗护理用品交易所( GHX )总裁兼首席执行官,这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团,在那里他工作了12年,最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。


Michael F. Mahoney,is the Lead Independent Director (since March 2025). He is the Chairman, President, and CEO of Boston Scientific Corporation and has been a CVS Health director since November 2023. He has been with Boston Scientific since October 2011, holding executive roles. Before Boston Scientific, he held leadership positions at Johnson & Johnson's DePuy franchise, Global Healthcare Exchange, and General Electric Medical Systems. He is on the board of Boston Scientific Corporation and has extensive experience in leading medical products companies, with skills in business development, health care services, technology, and finance.
Michael F. Mahoney,自2012年11月起担任总裁、首席执行官兼董事。他是波士顿科学国际有限公司的董事长、总裁兼首席执行官,自2023年11月起担任CVS Health Corporation董事。2011年10月17日起直到其现任职位期间,他担任公司总裁。作为公司的董事长,他专门负责心脏节律管理业务和内镜企业业务,以及某些固定企业要求。在加入该公司前, 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席,负责监督50000名员工和专营七家公司。2007年4月至2011年1月,Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长,负责骨科和神经科学业务。2001年1月至2007年3月,Mahoney先生担任全球医疗护理用品交易所( GHX )总裁兼首席执行官,这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团,在那里他工作了12年,最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。
Michael F. Mahoney,is the Lead Independent Director (since March 2025). He is the Chairman, President, and CEO of Boston Scientific Corporation and has been a CVS Health director since November 2023. He has been with Boston Scientific since October 2011, holding executive roles. Before Boston Scientific, he held leadership positions at Johnson & Johnson's DePuy franchise, Global Healthcare Exchange, and General Electric Medical Systems. He is on the board of Boston Scientific Corporation and has extensive experience in leading medical products companies, with skills in business development, health care services, technology, and finance.
Yoshiaki Fujimori

Yoshiaki Fujimori自2025年1月起担任Blaize Holdings,Inc.董事会成员。Fujimori先生自2016年6月起担任Takeda Pharmaceutical Company Limited的外部董事,自2016年7月起担任Boston Scientific Corporation的外部董事,自2018年8月起担任Oracle Japan Corporation的外部董事和董事长。自2023年7月起担任Corporate Support Research Institute Ltd.合伙人。自2017年2月起担任CVC Capital Partners Asia Pacific Japan Ltd.高级执行顾问。他担任CVC投资组合公司的外部董事,包括Riraku Co. Ltd.、Torai Co. Ltd.、Sogo Medical Co. Ltd.和Macromill Group Co.,Ltd.。他还自2018年1月起担任GENPACT Japan Ltd.的高级执行顾问。自2020年10月起担任Deloitte Tohmatsu Financial Advisory LLC高级顾问。自2024年9月起担任DigitalBridge Group Inc.的高级执行顾问,自2025年4月起担任DigitalBridge的投资组合公司JTor的外部董事。他拥有包括Hobart Inc.、Capital Z Inc.、Future Leadership Platform Inc.、Stainergy Inc.在内的这些私营公司的控股权。2011年至2016年,他担任东京证券交易所上市公司——LIXIL Group Company的总裁兼首席执行官。先前,他在通用电气工作了25年,担任过多个CEO职务,包括GE Plastics的首席执行官、GE Healthcare Asia的首席执行官、GE Money Asia的首席执行官和GE Asia的首席执行官。2019年至2021年担任Toshiba Corporation外部董事,2020年至2022年担任Shiseido Co. Ltd.外部董事。Fujimori先生获得了东京大学石油工程理学学士学位和Carnegie Mellon大学BINESS研究生院Biness Administration硕士学位,并担任Trtees董事会成员。


Yoshiaki Fujimori has served as a member of Board since January 2025. Mr. Fujimori has served as an outside director for Takeda Pharmaceutical Company Limited since June 2016 and Boston Scientific Corporation since July 2016, and as an outside director and Chairman for Oracle Japan Corporation since Augt 2018. He is a partner of Corporate Support Research Institute Ltd. since July 2023. He serves as a Senior Executive Advisor for CVC Capital Partners Asia Pacific Japan Ltd. since February 2017. He serves as outside director for those portfolio companies of CVC including Riraku Co. Ltd., Torai Co. Ltd. and Sogo Medical Co. Ltd. He also serves as a Senior Executive Advisor for GENPACT Japan Ltd. since January 2018. He serves as a Senior Advisor for Deloitte Tohmatsu Financial Advisory LLC since October 2020. He serves as a Senior Executive Advisor for DigitalBridge Group Inc. since September 2024. He owns controlling ownership of those private companies including Hobart Inc., Capital Z Inc., Future Leadership Platform Inc., and zStainergy Inc. Previoly he spent 25 years with General Electric for vario CEO roles including CEO of GE Plastics, CEO of GE Healthcare Asia, CEO of GE Money Asia and CEO of GE Asia. He served as outside director for Toshiba Corporation from 2019 to 2021 and Shiseido Co. Ltd. from 2020 to 2022.
Yoshiaki Fujimori自2025年1月起担任Blaize Holdings,Inc.董事会成员。Fujimori先生自2016年6月起担任Takeda Pharmaceutical Company Limited的外部董事,自2016年7月起担任Boston Scientific Corporation的外部董事,自2018年8月起担任Oracle Japan Corporation的外部董事和董事长。自2023年7月起担任Corporate Support Research Institute Ltd.合伙人。自2017年2月起担任CVC Capital Partners Asia Pacific Japan Ltd.高级执行顾问。他担任CVC投资组合公司的外部董事,包括Riraku Co. Ltd.、Torai Co. Ltd.、Sogo Medical Co. Ltd.和Macromill Group Co.,Ltd.。他还自2018年1月起担任GENPACT Japan Ltd.的高级执行顾问。自2020年10月起担任Deloitte Tohmatsu Financial Advisory LLC高级顾问。自2024年9月起担任DigitalBridge Group Inc.的高级执行顾问,自2025年4月起担任DigitalBridge的投资组合公司JTor的外部董事。他拥有包括Hobart Inc.、Capital Z Inc.、Future Leadership Platform Inc.、Stainergy Inc.在内的这些私营公司的控股权。2011年至2016年,他担任东京证券交易所上市公司——LIXIL Group Company的总裁兼首席执行官。先前,他在通用电气工作了25年,担任过多个CEO职务,包括GE Plastics的首席执行官、GE Healthcare Asia的首席执行官、GE Money Asia的首席执行官和GE Asia的首席执行官。2019年至2021年担任Toshiba Corporation外部董事,2020年至2022年担任Shiseido Co. Ltd.外部董事。Fujimori先生获得了东京大学石油工程理学学士学位和Carnegie Mellon大学BINESS研究生院Biness Administration硕士学位,并担任Trtees董事会成员。
Yoshiaki Fujimori has served as a member of Board since January 2025. Mr. Fujimori has served as an outside director for Takeda Pharmaceutical Company Limited since June 2016 and Boston Scientific Corporation since July 2016, and as an outside director and Chairman for Oracle Japan Corporation since Augt 2018. He is a partner of Corporate Support Research Institute Ltd. since July 2023. He serves as a Senior Executive Advisor for CVC Capital Partners Asia Pacific Japan Ltd. since February 2017. He serves as outside director for those portfolio companies of CVC including Riraku Co. Ltd., Torai Co. Ltd. and Sogo Medical Co. Ltd. He also serves as a Senior Executive Advisor for GENPACT Japan Ltd. since January 2018. He serves as a Senior Advisor for Deloitte Tohmatsu Financial Advisory LLC since October 2020. He serves as a Senior Executive Advisor for DigitalBridge Group Inc. since September 2024. He owns controlling ownership of those private companies including Hobart Inc., Capital Z Inc., Future Leadership Platform Inc., and zStainergy Inc. Previoly he spent 25 years with General Electric for vario CEO roles including CEO of GE Plastics, CEO of GE Healthcare Asia, CEO of GE Money Asia and CEO of GE Asia. He served as outside director for Toshiba Corporation from 2019 to 2021 and Shiseido Co. Ltd. from 2020 to 2022.
Jessica L. Mega

Jessica L. Mega自2015年3月起担任Verily Life Sciences LLC (Alphabet Inc.的子公司,专注于生命科学和医疗保健)的首席医疗和科学官。加入Verily之前,她曾担任Brigham & Women 's Hospital的心脏病专家和高级调查员(从2008年到2015年3月)。Mega博士也曾担任Harvard Medical School的教员和TIMI Study Group的高级研究员,在那里她帮助领导评估新型心血管疗法的国际试验,并指导遗传学项目。Mega博士负责监督Verily的临床和科学工作,专注于将技术创新和科学见解转化为改善患者预后的合作伙伴和项目。


Jessica L. Mega,is a leader at the intersection of technology, life sciences and healthcare. She co-founded Verily Life Sciences, LLC, a subsidiary of Alphabet Inc. focused on life sciences and healthcare, and served as Chief Medical and Scientific Officer from 2015 to January 2023. At Verily, Dr. Mega oversaw Verily's clinical and science efforts, focusing on translating technological innovations and scientific insights into partnerships and programs that improve patient outcomes. Prior to Verily, she served as a Cardiologist and Senior Investigator at Brigham and Women's Hospital from 2008 to 2015. Dr. Mega has also served as a faculty member at Harvard Medical School and with the TIMI Study Group, where she led large-scale international clinical trials evaluating novel cardiovascular therapies and directed the genetics program. Dr. Mega is currently a director of Danaher Corporation and is on the Board of Advisors at the Duke-Margolis Center for Health Policy, Stanford's Center for Digital Health and Research!America. Dr. Mega received an MD from Yale University School of Medicine, an MPH from Harvard School of Public Health and a BA from Stanford University.
Jessica L. Mega自2015年3月起担任Verily Life Sciences LLC (Alphabet Inc.的子公司,专注于生命科学和医疗保健)的首席医疗和科学官。加入Verily之前,她曾担任Brigham & Women 's Hospital的心脏病专家和高级调查员(从2008年到2015年3月)。Mega博士也曾担任Harvard Medical School的教员和TIMI Study Group的高级研究员,在那里她帮助领导评估新型心血管疗法的国际试验,并指导遗传学项目。Mega博士负责监督Verily的临床和科学工作,专注于将技术创新和科学见解转化为改善患者预后的合作伙伴和项目。
Jessica L. Mega,is a leader at the intersection of technology, life sciences and healthcare. She co-founded Verily Life Sciences, LLC, a subsidiary of Alphabet Inc. focused on life sciences and healthcare, and served as Chief Medical and Scientific Officer from 2015 to January 2023. At Verily, Dr. Mega oversaw Verily's clinical and science efforts, focusing on translating technological innovations and scientific insights into partnerships and programs that improve patient outcomes. Prior to Verily, she served as a Cardiologist and Senior Investigator at Brigham and Women's Hospital from 2008 to 2015. Dr. Mega has also served as a faculty member at Harvard Medical School and with the TIMI Study Group, where she led large-scale international clinical trials evaluating novel cardiovascular therapies and directed the genetics program. Dr. Mega is currently a director of Danaher Corporation and is on the Board of Advisors at the Duke-Margolis Center for Health Policy, Stanford's Center for Digital Health and Research!America. Dr. Mega received an MD from Yale University School of Medicine, an MPH from Harvard School of Public Health and a BA from Stanford University.
Susan E. Morano

Susan E. Morano,从2020年到2023年2月担任Johnson & Johnson MedTech业务发展和战略运营副总裁。在此之前,她从2012年开始担任Johnson & Johnson Medical Devices的业务发展副总裁,负责其医疗设备集团的许可、收购和剥离。在Johnson & Johnson任职期间,Morano女士还在六家运营公司担任多个职位,主要负责财务和业务发展职能,并担任MedTech领导团队的成员。她持有Villanova University的学士学位和Columbia Business School的工商管理硕士学位。


Susan E. Morano,is the former Vice President Business Development and Strategic Operations, Johnson & Johnson Medtech, having served in that position from 2020 through February 2023. Prior to this role, she served as Vice President Business Development, Johnson & Johnson Medical Devices, beginning in 2012, with responsibility for licensing, acquisitions and divestitures for its Medical Devices Group. In addition, during her time at Johnson & Johnson, Ms. Morano held a number of positions with increasing responsibility through six operating companies, primarily within Finance and Business Development, and is a former member of its MedTech Leadership Team. Ms. Morano received an MBA from Columbia University and a BA from Villanova University.
Susan E. Morano,从2020年到2023年2月担任Johnson & Johnson MedTech业务发展和战略运营副总裁。在此之前,她从2012年开始担任Johnson & Johnson Medical Devices的业务发展副总裁,负责其医疗设备集团的许可、收购和剥离。在Johnson & Johnson任职期间,Morano女士还在六家运营公司担任多个职位,主要负责财务和业务发展职能,并担任MedTech领导团队的成员。她持有Villanova University的学士学位和Columbia Business School的工商管理硕士学位。
Susan E. Morano,is the former Vice President Business Development and Strategic Operations, Johnson & Johnson Medtech, having served in that position from 2020 through February 2023. Prior to this role, she served as Vice President Business Development, Johnson & Johnson Medical Devices, beginning in 2012, with responsibility for licensing, acquisitions and divestitures for its Medical Devices Group. In addition, during her time at Johnson & Johnson, Ms. Morano held a number of positions with increasing responsibility through six operating companies, primarily within Finance and Business Development, and is a former member of its MedTech Leadership Team. Ms. Morano received an MBA from Columbia University and a BA from Villanova University.
Ellen M. Zane

Ellen M. Zane,塔夫茨医学中心名誉首席执行官,塔夫茨医学创始主席。赞恩女士此前曾在2004年至2011年担任塔夫茨医疗中心总裁兼首席执行官,当时她从该职位退休。在此之前,Zane女士曾担任Mass General Brigham(前身为Partners Healthcare System)的网络总裁,这是一个由哈佛附属麻省总医院和Brigham and Women''s Hospital赞助的医生/医院网络。赞恩女士此前还曾担任马萨诸塞州昆西市昆西医院的首席执行官。Zane女士目前担任Savista的董事,Savista是一家总部位于格鲁吉亚的私营公司,涉及医疗保健收入周期管理;Fiduciary Trust Company,一家私营财富管理公司;以及AgNovos Healthcare,LLC,一家私营医疗设备公司,专注于骨骼健康。Zane女士现任Haemonetics Corporation和Synchrony Financial的董事,此前曾担任Azenta, Inc.、Century Capital Management、Parexel International Corporation、Lincare Holdings Inc.和Press Ganey控股的董事。赞恩女士获得了库里学院、斯通希尔学院、本特利大学和马萨诸塞大学达特茅斯分校的荣誉学位。赞恩女士在美国天主教大学获得听力学和言语语言病理学硕士学位,在乔治华盛顿大学获得学士学位。


Ellen M. Zane,is CEO Emeritus at Tufts Medical Center and Founding Chair at Tufts Medicine. Ms. Zane previously served as President and Chief Executive Officer of Tufts Medical Center from 2004 to 2011 when she retired from this role. Prior to this, Ms. Zane served as Network President for Mass General Brigham (formerly Partners Healthcare System), a physician/hospital network sponsored by the Harvard-affiliated Massachusetts General Hospital and Brigham and Women's Hospital. Ms. Zane also previously served as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane currently is a director of Savista, a Georgia-based private company involved with healthcare revenue cycle management; Fiduciary Trust Company, a privately owned wealth management company; and AgNovos Healthcare, LLC, a privately held medical device company, focused on bone health. Ms. Zane is currently a director of Haemonetics Corporation and Synchrony Financial and previously served as a director of Azenta, Inc., Century Capital Management, Parexel International Corporation, Lincare Holdings Inc. and Press Ganey Holdings. Ms. Zane has received Honorary Degrees from Curry College, Stonehill College, Bentley University and University of Massachusetts-Dartmouth. Ms. Zane received an MA in audiology and speech-language pathology from Catholic University of America and a BA from George Washington University.
Ellen M. Zane,塔夫茨医学中心名誉首席执行官,塔夫茨医学创始主席。赞恩女士此前曾在2004年至2011年担任塔夫茨医疗中心总裁兼首席执行官,当时她从该职位退休。在此之前,Zane女士曾担任Mass General Brigham(前身为Partners Healthcare System)的网络总裁,这是一个由哈佛附属麻省总医院和Brigham and Women''s Hospital赞助的医生/医院网络。赞恩女士此前还曾担任马萨诸塞州昆西市昆西医院的首席执行官。Zane女士目前担任Savista的董事,Savista是一家总部位于格鲁吉亚的私营公司,涉及医疗保健收入周期管理;Fiduciary Trust Company,一家私营财富管理公司;以及AgNovos Healthcare,LLC,一家私营医疗设备公司,专注于骨骼健康。Zane女士现任Haemonetics Corporation和Synchrony Financial的董事,此前曾担任Azenta, Inc.、Century Capital Management、Parexel International Corporation、Lincare Holdings Inc.和Press Ganey控股的董事。赞恩女士获得了库里学院、斯通希尔学院、本特利大学和马萨诸塞大学达特茅斯分校的荣誉学位。赞恩女士在美国天主教大学获得听力学和言语语言病理学硕士学位,在乔治华盛顿大学获得学士学位。
Ellen M. Zane,is CEO Emeritus at Tufts Medical Center and Founding Chair at Tufts Medicine. Ms. Zane previously served as President and Chief Executive Officer of Tufts Medical Center from 2004 to 2011 when she retired from this role. Prior to this, Ms. Zane served as Network President for Mass General Brigham (formerly Partners Healthcare System), a physician/hospital network sponsored by the Harvard-affiliated Massachusetts General Hospital and Brigham and Women's Hospital. Ms. Zane also previously served as Chief Executive Officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane currently is a director of Savista, a Georgia-based private company involved with healthcare revenue cycle management; Fiduciary Trust Company, a privately owned wealth management company; and AgNovos Healthcare, LLC, a privately held medical device company, focused on bone health. Ms. Zane is currently a director of Haemonetics Corporation and Synchrony Financial and previously served as a director of Azenta, Inc., Century Capital Management, Parexel International Corporation, Lincare Holdings Inc. and Press Ganey Holdings. Ms. Zane has received Honorary Degrees from Curry College, Stonehill College, Bentley University and University of Massachusetts-Dartmouth. Ms. Zane received an MA in audiology and speech-language pathology from Catholic University of America and a BA from George Washington University.
Edward J. Ludwig

Edward J. Ludwig于2011年10月31日进入公司董事会。他于2012年7月在贝克顿公司、迪金森公司和BD公司担任董事长职务。他于1979年加入BD 公司,自2000年1月至2011年9月期间内他担任首席执行官、总裁、财务总监以及其他职务。再加入BD公司之前,他在永道会计师事务所(现在被称为普华永道律师事务所)担任高级审计师,在此期间内,他获得了注册会计师资格证。并且在基德公司担任财务与策略分析师。他在安泰保险公司董事会担任首席董事,并在财务委员会董事会担任主席。他也在波士顿科学公司董事会任职。他在哈肯萨克大学医学中心网络董事会担任副董事长,他是战略咨询委员会资金使用费部门的一员并在POCARED公司担任主管。他是更高职员领导中心董事会成员之一。他任职于哥伦比亚商学院监督委员会。他在美国先进医疗技术协会担任董事会主席,美国先进医疗技术协会是世界上最大的医疗技术协会。他在约翰霍普金斯彭博公共卫生学院健康咨询委员会担任主席。他拥有圣十字学院的金融会计学士学位以及哥伦比亚大学的金融工商管理学硕士学位。


Edward J. Ludwig,is the former Chairman of the Board of Becton, Dickinson and Company (BDX), a global medical technology company, having served in that position from February 2002 through June 2012. He also served as BDX's Chief Executive Officer from January 2000 to September 2011 and as its President from May 1999 to December 2008. Mr. Ludwig joined BDX as a senior financial analyst in 1979. Prior to joining BDX, Mr. Ludwig served as a senior auditor with Coopers and Lybrand (now PricewaterhouseCoopers), where he earned his CPA, and as a financial and strategic analyst at Kidde, Inc. Mr. Ludwig was a member of the board of directors of POCARED Diagnostics Ltd, a privately held company focused on infectious disease diagnostics from 2013 to 2022. He formerly served as a director of CVS Health Corporation, Aetna, Inc., Xylem, Inc. and as Vice Chair of the board of trustees of the Hackensack University Medical Center Network. Mr. Ludwig received an MBA from Columbia University and a BA in economics and accounting from The College of Holy Cross.
Edward J. Ludwig于2011年10月31日进入公司董事会。他于2012年7月在贝克顿公司、迪金森公司和BD公司担任董事长职务。他于1979年加入BD 公司,自2000年1月至2011年9月期间内他担任首席执行官、总裁、财务总监以及其他职务。再加入BD公司之前,他在永道会计师事务所(现在被称为普华永道律师事务所)担任高级审计师,在此期间内,他获得了注册会计师资格证。并且在基德公司担任财务与策略分析师。他在安泰保险公司董事会担任首席董事,并在财务委员会董事会担任主席。他也在波士顿科学公司董事会任职。他在哈肯萨克大学医学中心网络董事会担任副董事长,他是战略咨询委员会资金使用费部门的一员并在POCARED公司担任主管。他是更高职员领导中心董事会成员之一。他任职于哥伦比亚商学院监督委员会。他在美国先进医疗技术协会担任董事会主席,美国先进医疗技术协会是世界上最大的医疗技术协会。他在约翰霍普金斯彭博公共卫生学院健康咨询委员会担任主席。他拥有圣十字学院的金融会计学士学位以及哥伦比亚大学的金融工商管理学硕士学位。
Edward J. Ludwig,is the former Chairman of the Board of Becton, Dickinson and Company (BDX), a global medical technology company, having served in that position from February 2002 through June 2012. He also served as BDX's Chief Executive Officer from January 2000 to September 2011 and as its President from May 1999 to December 2008. Mr. Ludwig joined BDX as a senior financial analyst in 1979. Prior to joining BDX, Mr. Ludwig served as a senior auditor with Coopers and Lybrand (now PricewaterhouseCoopers), where he earned his CPA, and as a financial and strategic analyst at Kidde, Inc. Mr. Ludwig was a member of the board of directors of POCARED Diagnostics Ltd, a privately held company focused on infectious disease diagnostics from 2013 to 2022. He formerly served as a director of CVS Health Corporation, Aetna, Inc., Xylem, Inc. and as Vice Chair of the board of trustees of the Hackensack University Medical Center Network. Mr. Ludwig received an MBA from Columbia University and a BA in economics and accounting from The College of Holy Cross.
John E. Sununu

John E. Sununu,自2009年4月起担任波士顿科技公司的董事。从2003年至2009年,他曾担任新罕布什尔州的参议员。他是银行业、商业、金融业和外交关系委员会的成员;他被任命为联合国大会的国会代表。在当选为参议院议员前,从1996年至2002年,他曾担任三届来自新罕布什尔州第一区的众议院议员。他是预算委员会的副主席和拨款委员会的成员。在过去在国会的十二年,他起草并帮助通过几个重要的法例,包括互联网免税法案、幸存者福利法和新英格兰荒野保护法。在国会任职前,他曾担Teletrol系统公司的任首席财务官,这是一家建立控制系统的制造商。他同时还任职于时代华纳有线公司。他持有麻省理工学院的机械工程学士学位和哈佛商学院的工商管理硕士学位。


John E. Sununu,served as a U.S. Senator from New Hampshire from 2003 to 2009. He was a member of the Committees on Banking, Commerce, Finance and Foreign Relations, and he was appointed the Congressional Representative to the United Nations General Assembly. Before his election to the Senate, Senator Sununu served three terms as a member of the U.S. House of Representatives from New Hampshire's 1st District from 1996 to 2002, where he was Vice Chairman of the Budget Committee and a member of the Appropriations Committee. During his twelve years in Congress, he drafted and helped pass several important pieces of legislation, including the Internet Tax Freedom Act, the Survivors Benefit Act and the New England Wilderness Act. Prior to serving in Congress, Senator Sununu served as Chief Financial Officer for Teletrol Systems, a manufacturer of building control systems. Senator Sununu formerly served as a Council Member of Lloyds of London and as a director of Time Warner Cable Inc. and several private and charitable entities. Senator Sununu is a director of BlueRiver Acquisition Corp. Senator Sununu received an MBA from Harvard University and an MS and a BA in mechanical engineering from Massachusetts Institute of Technology.
John E. Sununu,自2009年4月起担任波士顿科技公司的董事。从2003年至2009年,他曾担任新罕布什尔州的参议员。他是银行业、商业、金融业和外交关系委员会的成员;他被任命为联合国大会的国会代表。在当选为参议院议员前,从1996年至2002年,他曾担任三届来自新罕布什尔州第一区的众议院议员。他是预算委员会的副主席和拨款委员会的成员。在过去在国会的十二年,他起草并帮助通过几个重要的法例,包括互联网免税法案、幸存者福利法和新英格兰荒野保护法。在国会任职前,他曾担Teletrol系统公司的任首席财务官,这是一家建立控制系统的制造商。他同时还任职于时代华纳有线公司。他持有麻省理工学院的机械工程学士学位和哈佛商学院的工商管理硕士学位。
John E. Sununu,served as a U.S. Senator from New Hampshire from 2003 to 2009. He was a member of the Committees on Banking, Commerce, Finance and Foreign Relations, and he was appointed the Congressional Representative to the United Nations General Assembly. Before his election to the Senate, Senator Sununu served three terms as a member of the U.S. House of Representatives from New Hampshire's 1st District from 1996 to 2002, where he was Vice Chairman of the Budget Committee and a member of the Appropriations Committee. During his twelve years in Congress, he drafted and helped pass several important pieces of legislation, including the Internet Tax Freedom Act, the Survivors Benefit Act and the New England Wilderness Act. Prior to serving in Congress, Senator Sununu served as Chief Financial Officer for Teletrol Systems, a manufacturer of building control systems. Senator Sununu formerly served as a Council Member of Lloyds of London and as a director of Time Warner Cable Inc. and several private and charitable entities. Senator Sununu is a director of BlueRiver Acquisition Corp. Senator Sununu received an MBA from Harvard University and an MS and a BA in mechanical engineering from Massachusetts Institute of Technology.
David S. Wichmann

David S. Wichmann,自1998年以来,担任联合健康集团的运营和技术总裁兼首席财务官,一家多元化的健康福祉公司。自2011年1月以来,他在联合健康集团担任多个行政职务,包括运营和技术部总裁,商业市场集团总裁、联合健康集团首席营运官,专业护理服务部总裁兼首席执行官、和公司发展部高级副总裁。1995年至1998年,担任安达信律师事务所的合伙人。自1992年至1994年,担任高级机械公司的财务总监。担任审计委员会、补偿和执行委员会的成员。


David S. Wichmann,is the Co-Founder of Jory Capital and former Chief Executive Officer of UnitedHealth Group Incorporated, having served in that position from September 2017 through March 2021. Prior to this role, he served as President, UnitedHealth Group, beginning in November 2014, with oversight responsibility for all of UnitedHealthcare's domestic and international businesses, and for overall UnitedHealth Group performance, and as Chief Financial Officer of the UnitedHealth Group from 2011 until 2016. In addition, during his time at UnitedHealth Group, he held positions as President, UnitedHealthcare; President and Chief Executive Officer, Specialized Care Services (now OptumHealth); and Senior Vice President, Corporate Development. Prior to joining UnitedHealth Group, Mr. Wichmann was a partner at Arthur Andersen & Co. and Chief Financial Officer of Advanced Machine Company. He is currently a director of Privia Health Group, Inc. and serves on the boards of certain privately held companies where Jory Capital currently maintains an investment. Mr. Wichmann previously served on the board of directors of UnitedHealth Group Incorporated and Tennant Company. Mr. Wichmann received a BS in accounting from Illinois State University.
David S. Wichmann,自1998年以来,担任联合健康集团的运营和技术总裁兼首席财务官,一家多元化的健康福祉公司。自2011年1月以来,他在联合健康集团担任多个行政职务,包括运营和技术部总裁,商业市场集团总裁、联合健康集团首席营运官,专业护理服务部总裁兼首席执行官、和公司发展部高级副总裁。1995年至1998年,担任安达信律师事务所的合伙人。自1992年至1994年,担任高级机械公司的财务总监。担任审计委员会、补偿和执行委员会的成员。
David S. Wichmann,is the Co-Founder of Jory Capital and former Chief Executive Officer of UnitedHealth Group Incorporated, having served in that position from September 2017 through March 2021. Prior to this role, he served as President, UnitedHealth Group, beginning in November 2014, with oversight responsibility for all of UnitedHealthcare's domestic and international businesses, and for overall UnitedHealth Group performance, and as Chief Financial Officer of the UnitedHealth Group from 2011 until 2016. In addition, during his time at UnitedHealth Group, he held positions as President, UnitedHealthcare; President and Chief Executive Officer, Specialized Care Services (now OptumHealth); and Senior Vice President, Corporate Development. Prior to joining UnitedHealth Group, Mr. Wichmann was a partner at Arthur Andersen & Co. and Chief Financial Officer of Advanced Machine Company. He is currently a director of Privia Health Group, Inc. and serves on the boards of certain privately held companies where Jory Capital currently maintains an investment. Mr. Wichmann previously served on the board of directors of UnitedHealth Group Incorporated and Tennant Company. Mr. Wichmann received a BS in accounting from Illinois State University.
Cheryl Pegus

Cheryl Pegus于1996年开始她的医疗保健管理职业生涯,担任Pfizer Inc.的心血管医学总监。Pegus博士自2022年底以来一直担任Morgan Health的合伙人。她也是Walmart, Inc.的健康和保健执行副总裁。Pegus博士于2020年加入沃尔玛,此前她在Cambia Health Solutions担任付款人和消费者健康相关职位数年。2013年至2020年,她担任Caluent LLC的总裁。2007年至2012年,她曾担任Symcare Personalized Health Solutions Inc.的首席医疗官,后来担任Walgreens Company的首席医疗官。Pegus博士曾担任多个医疗组织的董事会成员,包括the Patient Centered Outcomes Research Institute和the American Heart Association。在担任大型管理职位之前,她是纽约医疗机构的心脏病专家、临床研究员和研究员,包括康奈尔大学的The Joan & Sanford I. Weill医学院和Memorial Sloan Kettering癌症中心。Pegus博士目前担任Boston Scientific Corporation的董事会成员。


Cheryl Pegus,recently served as a partner at Morgan Health, where, from November 2022 to May 2024, she supported the organization's strategic investments and broader efforts to improve the quality and affordability of employer-sponsored health care. Dr. Pegus is president of Caluent, LLC, a healthcare analytics and advisory company she has owned since 2012. Dr. Pegus previously served as executive vice president of Health & Wellness for Walmart from December 2020 through March 2023, where she led the company's health care businesses and served as a senior advisor. Prior to that, Dr. Pegus served as chief medical officer and president of Consumer Health Solutions for Cambia Health Solutions from September 2018 to December 2020. Dr. Pegus also served as the first chief medical officer of Walgreens from 2010 to 2013, and from 2007 to 2010, as general manager and chief medical officer of SymCare Personalized Health Solutions, Inc., a diabetes-focused division of Johnson & Johnson. Prior to that, Dr. Pegus served as a medical director at Aetna and Pfizer. She began her career in private practice as a cardiologist. Dr. Pegus is currently a member of the board of directors of Concentra, a provider of occupational health services. Dr. Pegus is co-founder of A New Beat, an organization focused on advancing cardiovascular health and supporting the career growth of emerging leaders in the field of cardiology, and currently serves on the boards of private organizations, including the American Heart Association. Dr. Pegus previously served as a director of several public companies, including Phreesia, Inc., Tactile Systems Technology, Inc. and Cogentix Medical, Inc. Dr. Pegus received an MD from Weill Cornell Medical College, an MPH from Columbia University Mailman School of Public Health, and a BA from Brandeis University.
Cheryl Pegus于1996年开始她的医疗保健管理职业生涯,担任Pfizer Inc.的心血管医学总监。Pegus博士自2022年底以来一直担任Morgan Health的合伙人。她也是Walmart, Inc.的健康和保健执行副总裁。Pegus博士于2020年加入沃尔玛,此前她在Cambia Health Solutions担任付款人和消费者健康相关职位数年。2013年至2020年,她担任Caluent LLC的总裁。2007年至2012年,她曾担任Symcare Personalized Health Solutions Inc.的首席医疗官,后来担任Walgreens Company的首席医疗官。Pegus博士曾担任多个医疗组织的董事会成员,包括the Patient Centered Outcomes Research Institute和the American Heart Association。在担任大型管理职位之前,她是纽约医疗机构的心脏病专家、临床研究员和研究员,包括康奈尔大学的The Joan & Sanford I. Weill医学院和Memorial Sloan Kettering癌症中心。Pegus博士目前担任Boston Scientific Corporation的董事会成员。
Cheryl Pegus,recently served as a partner at Morgan Health, where, from November 2022 to May 2024, she supported the organization's strategic investments and broader efforts to improve the quality and affordability of employer-sponsored health care. Dr. Pegus is president of Caluent, LLC, a healthcare analytics and advisory company she has owned since 2012. Dr. Pegus previously served as executive vice president of Health & Wellness for Walmart from December 2020 through March 2023, where she led the company's health care businesses and served as a senior advisor. Prior to that, Dr. Pegus served as chief medical officer and president of Consumer Health Solutions for Cambia Health Solutions from September 2018 to December 2020. Dr. Pegus also served as the first chief medical officer of Walgreens from 2010 to 2013, and from 2007 to 2010, as general manager and chief medical officer of SymCare Personalized Health Solutions, Inc., a diabetes-focused division of Johnson & Johnson. Prior to that, Dr. Pegus served as a medical director at Aetna and Pfizer. She began her career in private practice as a cardiologist. Dr. Pegus is currently a member of the board of directors of Concentra, a provider of occupational health services. Dr. Pegus is co-founder of A New Beat, an organization focused on advancing cardiovascular health and supporting the career growth of emerging leaders in the field of cardiology, and currently serves on the boards of private organizations, including the American Heart Association. Dr. Pegus previously served as a director of several public companies, including Phreesia, Inc., Tactile Systems Technology, Inc. and Cogentix Medical, Inc. Dr. Pegus received an MD from Weill Cornell Medical College, an MPH from Columbia University Mailman School of Public Health, and a BA from Brandeis University.
David C. Habiger

David C. Habiger,是市场研究和数据分析公司J.D. Power的总裁兼首席执行官。在2018年3月加入J.D. Power担任CEO之前,他于2016年1月开始创立Silicon Media Partners并担任合伙人,2013年10月至2020年10月在私募股权公司Silver Lake Partners担任高级顾问,2013年1月至2019年10月在风险投资公司Prizker Group担任风险合伙人。Habiger先生通过2016年6月将Textura Corporation出售给甲骨文担任首席执行官,并通过2012年7月将其出售给思科担任NDS的首席执行官。在其职业生涯的早期,他曾在Sonic Solutions担任越来越重要的职务,包括在2011年初通过将该公司出售给Rovi Corporation担任该公司的首席执行官。Habiger先生是芝加哥联邦储备委员会的董事,他在治理、人力资源和SABOR(系统活动、银行运营和风险)委员会任职。他还是多个公共和私营董事会的董事,包括全球工业电池制造公司EnerSys、社交媒体和软件公司Reddit,Inc.以及消费和娱乐授权公司Xperi Inc.,以及拉什大学医学中心的董事会成员。Habiger先生获得了芝加哥大学的工商管理硕士学位和圣诺伯特学院的工商管理学士学位。


David C. Habiger,is the President and Chief Executive Officer of J.D. Power, a market research and data analytics company. Prior to joining J.D. Power as its CEO in March 2018, he founded and was partner of Silicon Media Partners beginning in January 2016, served as a senior advisor at Silver Lake Partners, a private equity firm, from October 2013 to October 2020, and was a venture partner at Prizker Group, a venture capital firm, from January 2013 to October 2019. Mr. Habiger served as Chief Executive Officer of Textura Corporation through its sale to Oracle in June of 2016 and served as the Chief Executive Officer of NDS through its sale to Cisco in July 2012. Earlier in his career, he held positions of increasing responsibility at Sonic Solutions, including serving as its Chief Executive Officer through its sale to Rovi Corporation in early 2011. Mr. Habiger is a director on the Chicago Federal Reserve Board where he serves on the Governance, Human Resources and SABOR (Systems Activities, Bank Operations and Risk) Committees. He is also a director of several public and private boards, including EnerSys, a global industrial battery manufacturing company, Reddit, Inc., a social media and software company, and Xperi Inc., a consumer and entertainment licensing company, and a member of the board of trustees at Rush University Medical Center. Mr. Habiger received an MBA from The University of Chicago and a BA in business administration from St. Norbert College.
David C. Habiger,是市场研究和数据分析公司J.D. Power的总裁兼首席执行官。在2018年3月加入J.D. Power担任CEO之前,他于2016年1月开始创立Silicon Media Partners并担任合伙人,2013年10月至2020年10月在私募股权公司Silver Lake Partners担任高级顾问,2013年1月至2019年10月在风险投资公司Prizker Group担任风险合伙人。Habiger先生通过2016年6月将Textura Corporation出售给甲骨文担任首席执行官,并通过2012年7月将其出售给思科担任NDS的首席执行官。在其职业生涯的早期,他曾在Sonic Solutions担任越来越重要的职务,包括在2011年初通过将该公司出售给Rovi Corporation担任该公司的首席执行官。Habiger先生是芝加哥联邦储备委员会的董事,他在治理、人力资源和SABOR(系统活动、银行运营和风险)委员会任职。他还是多个公共和私营董事会的董事,包括全球工业电池制造公司EnerSys、社交媒体和软件公司Reddit,Inc.以及消费和娱乐授权公司Xperi Inc.,以及拉什大学医学中心的董事会成员。Habiger先生获得了芝加哥大学的工商管理硕士学位和圣诺伯特学院的工商管理学士学位。
David C. Habiger,is the President and Chief Executive Officer of J.D. Power, a market research and data analytics company. Prior to joining J.D. Power as its CEO in March 2018, he founded and was partner of Silicon Media Partners beginning in January 2016, served as a senior advisor at Silver Lake Partners, a private equity firm, from October 2013 to October 2020, and was a venture partner at Prizker Group, a venture capital firm, from January 2013 to October 2019. Mr. Habiger served as Chief Executive Officer of Textura Corporation through its sale to Oracle in June of 2016 and served as the Chief Executive Officer of NDS through its sale to Cisco in July 2012. Earlier in his career, he held positions of increasing responsibility at Sonic Solutions, including serving as its Chief Executive Officer through its sale to Rovi Corporation in early 2011. Mr. Habiger is a director on the Chicago Federal Reserve Board where he serves on the Governance, Human Resources and SABOR (Systems Activities, Bank Operations and Risk) Committees. He is also a director of several public and private boards, including EnerSys, a global industrial battery manufacturing company, Reddit, Inc., a social media and software company, and Xperi Inc., a consumer and entertainment licensing company, and a member of the board of trustees at Rush University Medical Center. Mr. Habiger received an MBA from The University of Chicago and a BA in business administration from St. Norbert College.

高管简历

中英对照 |  中文 |  英文
Michael F. Mahoney

Michael F. Mahoney,自2012年11月起担任总裁、首席执行官兼董事。他是波士顿科学国际有限公司的董事长、总裁兼首席执行官,自2023年11月起担任CVS Health Corporation董事。2011年10月17日起直到其现任职位期间,他担任公司总裁。作为公司的董事长,他专门负责心脏节律管理业务和内镜企业业务,以及某些固定企业要求。在加入该公司前, 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席,负责监督50000名员工和专营七家公司。2007年4月至2011年1月,Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长,负责骨科和神经科学业务。2001年1月至2007年3月,Mahoney先生担任全球医疗护理用品交易所( GHX )总裁兼首席执行官,这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团,在那里他工作了12年,最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。


Michael F. Mahoney,is the Lead Independent Director (since March 2025). He is the Chairman, President, and CEO of Boston Scientific Corporation and has been a CVS Health director since November 2023. He has been with Boston Scientific since October 2011, holding executive roles. Before Boston Scientific, he held leadership positions at Johnson & Johnson's DePuy franchise, Global Healthcare Exchange, and General Electric Medical Systems. He is on the board of Boston Scientific Corporation and has extensive experience in leading medical products companies, with skills in business development, health care services, technology, and finance.
Michael F. Mahoney,自2012年11月起担任总裁、首席执行官兼董事。他是波士顿科学国际有限公司的董事长、总裁兼首席执行官,自2023年11月起担任CVS Health Corporation董事。2011年10月17日起直到其现任职位期间,他担任公司总裁。作为公司的董事长,他专门负责心脏节律管理业务和内镜企业业务,以及某些固定企业要求。在加入该公司前, 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席,负责监督50000名员工和专营七家公司。2007年4月至2011年1月,Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长,负责骨科和神经科学业务。2001年1月至2007年3月,Mahoney先生担任全球医疗护理用品交易所( GHX )总裁兼首席执行官,这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团,在那里他工作了12年,最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。
Michael F. Mahoney,is the Lead Independent Director (since March 2025). He is the Chairman, President, and CEO of Boston Scientific Corporation and has been a CVS Health director since November 2023. He has been with Boston Scientific since October 2011, holding executive roles. Before Boston Scientific, he held leadership positions at Johnson & Johnson's DePuy franchise, Global Healthcare Exchange, and General Electric Medical Systems. He is on the board of Boston Scientific Corporation and has extensive experience in leading medical products companies, with skills in business development, health care services, technology, and finance.
John B. Sorenson

John B. Sorenson是Boston Scientific Corporation全球运营执行副总裁,自2022年5月起担任该职位。在这个职位上,他负责监督全球供应链、质量和监管事务、全球企业卓越、信息技术、安全、企业研发、航空、全球设施、房地产和环境健康与安全。在担任现职之前,他曾于2021年9月至2022年5月担任全球供应链高级副总裁。在这个职位上,他负责Boston Scientific Corporation产品的全球制造和分销。他曾于2014年11月至2021年9月担任制造和供应链高级副总裁,并于2008年至2014年担任多站点运营副总裁。Sorenson先生曾在公司担任多个运营职位,支持心律管理、神经调节、介入心脏病学、外周介入和结构性心脏业务,并拥有20多年的医疗器械制造经验。他是Boston Scientific Corporation全球包容性理事会的成员,并担任Boston Scientific Corporation青年专业人员网络雇员资源小组的执行赞助人。在加入Boston Scientific Corporation之前,他是QRS Diagnostic的总裁兼首席运营官,并在Federal Cartridge担任制造管理职位。Sorenson在古斯塔夫斯·阿道夫学院获得经济学学士学位,在Minnesota大学获得工商管理硕士学位。


John B. Sorenson,is Executive Vice President, Global Operations, a position he has held since May 2022. In this role, he oversees Global Supply Chain, Quality and Regulatory Affairs, Global Enterprise Excellence, Information Technology, Security, Corporate Research and Development, Aviation, Global Facilities, Real Estate and Environmental Health and Safety. Since joining the Company in 1996, Mr. Sorenson has supported the Cardiac Rhythm Management, Neuromodulation, Interventional Cardiology, Peripheral Interventions and Structural Heart businesses in a variety of operations positions, and, most recently, served as Senior Vice President, Manufacturing and Supply, later changed to Senior Vice President, Global Supply Chain (2014 to 2022), responsible for global manufacturing and distribution of products. He is a member of Global Council for Inclusion and serves as the executive sponsor for Young Professionals Network employee resource group. Mr. Sorenson received an MBA from the University of Minnesota and a BA in Economics from Gustavus Adolphus College.
John B. Sorenson是Boston Scientific Corporation全球运营执行副总裁,自2022年5月起担任该职位。在这个职位上,他负责监督全球供应链、质量和监管事务、全球企业卓越、信息技术、安全、企业研发、航空、全球设施、房地产和环境健康与安全。在担任现职之前,他曾于2021年9月至2022年5月担任全球供应链高级副总裁。在这个职位上,他负责Boston Scientific Corporation产品的全球制造和分销。他曾于2014年11月至2021年9月担任制造和供应链高级副总裁,并于2008年至2014年担任多站点运营副总裁。Sorenson先生曾在公司担任多个运营职位,支持心律管理、神经调节、介入心脏病学、外周介入和结构性心脏业务,并拥有20多年的医疗器械制造经验。他是Boston Scientific Corporation全球包容性理事会的成员,并担任Boston Scientific Corporation青年专业人员网络雇员资源小组的执行赞助人。在加入Boston Scientific Corporation之前,他是QRS Diagnostic的总裁兼首席运营官,并在Federal Cartridge担任制造管理职位。Sorenson在古斯塔夫斯·阿道夫学院获得经济学学士学位,在Minnesota大学获得工商管理硕士学位。
John B. Sorenson,is Executive Vice President, Global Operations, a position he has held since May 2022. In this role, he oversees Global Supply Chain, Quality and Regulatory Affairs, Global Enterprise Excellence, Information Technology, Security, Corporate Research and Development, Aviation, Global Facilities, Real Estate and Environmental Health and Safety. Since joining the Company in 1996, Mr. Sorenson has supported the Cardiac Rhythm Management, Neuromodulation, Interventional Cardiology, Peripheral Interventions and Structural Heart businesses in a variety of operations positions, and, most recently, served as Senior Vice President, Manufacturing and Supply, later changed to Senior Vice President, Global Supply Chain (2014 to 2022), responsible for global manufacturing and distribution of products. He is a member of Global Council for Inclusion and serves as the executive sponsor for Young Professionals Network employee resource group. Mr. Sorenson received an MBA from the University of Minnesota and a BA in Economics from Gustavus Adolphus College.
Eric Thepaut

Eric Thepaut是Boston Scientific Corporation执行副总裁兼欧洲、中东和非洲总裁,自2020年2月起担任该职位。在担任现职之前,他曾于2017年12月至2020年1月担任欧洲、中东和非洲高级副总裁兼总裁,并于2015年1月至2017年12月担任欧洲高级副总裁兼总裁。2012年12月至2015年12月,他还担任欧洲介入心脏病学和结构心脏副总裁。他于1996年加入Boston Scientific Corporation欧洲公司,担任业务财务经理,并在市场营销和财务领域担任越来越重要的职务,包括欧洲财务副总裁、法国总经理和副总裁,以及法国集团的总经理和副总裁,Boston Scientific Corporation由法国、比荷卢和中东北非组成。Thepaut先生是Boston Scientific Corporation全球包容理事会的成员。在加入Boston Scientific Corporation公司之前,Thepaut先生曾在Nestle 担任财务运营和审计管理职务,在Apple, Inc.(当时的Apple Computer, Inc.)担任财务规划和分析管理职务。Thepaut先生在Paris Dauphine大学获得了工商管理硕士学位。


Eric Thepaut,is Boston Scientific Corporation Executive Vice President and President, Europe, Middle East and Africa, a position he has held since February 2020. Prior to his current role, he was Senior Vice President and President, Europe, Middle East and Africa from December 2017 to January 2020, and Senior Vice President and President, Europe from January 2015 to December 2017. He also served as Vice President, Interventional Cardiology & Structural Heart, Europe from December 2012 to December 2015. He joined Boston Scientific Europe in 1996 as a business finance manager and earned roles of increasing responsibility in marketing and finance including Vice President, Finance, Europe, General Manager and Vice President, France, and General Manager and Vice President of the France Group, comprised of France, Benelux and Middle East North Africa. Mr. Thépaut is a member of Boston Scientific Corporation Global Council for Inclusion. Before joining the Company, Mr. Thépaut held management positions in Treasury Operations and Auditing at Nestlé and Financial Planning and Analysis at Apple, Inc. (then Apple Computer, Inc.). Mr. Thépaut earned his M.B.A. at Paris Dauphine University.
Eric Thepaut是Boston Scientific Corporation执行副总裁兼欧洲、中东和非洲总裁,自2020年2月起担任该职位。在担任现职之前,他曾于2017年12月至2020年1月担任欧洲、中东和非洲高级副总裁兼总裁,并于2015年1月至2017年12月担任欧洲高级副总裁兼总裁。2012年12月至2015年12月,他还担任欧洲介入心脏病学和结构心脏副总裁。他于1996年加入Boston Scientific Corporation欧洲公司,担任业务财务经理,并在市场营销和财务领域担任越来越重要的职务,包括欧洲财务副总裁、法国总经理和副总裁,以及法国集团的总经理和副总裁,Boston Scientific Corporation由法国、比荷卢和中东北非组成。Thepaut先生是Boston Scientific Corporation全球包容理事会的成员。在加入Boston Scientific Corporation公司之前,Thepaut先生曾在Nestle 担任财务运营和审计管理职务,在Apple, Inc.(当时的Apple Computer, Inc.)担任财务规划和分析管理职务。Thepaut先生在Paris Dauphine大学获得了工商管理硕士学位。
Eric Thepaut,is Boston Scientific Corporation Executive Vice President and President, Europe, Middle East and Africa, a position he has held since February 2020. Prior to his current role, he was Senior Vice President and President, Europe, Middle East and Africa from December 2017 to January 2020, and Senior Vice President and President, Europe from January 2015 to December 2017. He also served as Vice President, Interventional Cardiology & Structural Heart, Europe from December 2012 to December 2015. He joined Boston Scientific Europe in 1996 as a business finance manager and earned roles of increasing responsibility in marketing and finance including Vice President, Finance, Europe, General Manager and Vice President, France, and General Manager and Vice President of the France Group, comprised of France, Benelux and Middle East North Africa. Mr. Thépaut is a member of Boston Scientific Corporation Global Council for Inclusion. Before joining the Company, Mr. Thépaut held management positions in Treasury Operations and Auditing at Nestlé and Financial Planning and Analysis at Apple, Inc. (then Apple Computer, Inc.). Mr. Thépaut earned his M.B.A. at Paris Dauphine University.
Arthur C. Butcher

Arthur C. Butcher是Boston Scientific Corporation执行副总裁兼MedSurg和亚太区集团总裁,自2022年5月起担任该职位。在这个职位上,他负责监督亚太地区,以及Boston Scientific Corporation泌尿外科内窥镜检查和神经调节业务。在担任现职之前,Butcher先生于2020年2月至2022年5月担任Boston Scientific Corporation执行副总裁兼亚太区总裁,负责Boston Scientific Corporation在亚太地区所有部门的全部产品组合的商业化。此前,Butcher曾担任Boston Scientific Corporation高级副总裁兼内窥镜总裁,2016年7月至2020年2月担任该职位。在这个职位上,他负责开发用于治疗胃肠道和肺部疾病的侵入性较小的设备并将其推向市场。2014年8月至2016年6月,他还担任日本内窥镜副总裁兼总经理。Butcher先生曾在内窥镜和泌尿外科部门担任过多个营销和战略规划管理职位,包括2011年4月至2014年8月的内窥镜部门全球营销副总裁,以及泌尿外科和女性健康部门新业务发展和战略规划副总裁。自1997年加入Boston Scientific Corporation公司以来,Butcher先生一直担任管理职务,责任越来越大,在各个部门都有丰富的经验。Butcher先生是Boston Scientific Corporation全球包容性理事会的成员,也是中国上市医疗器械公司Acotec Scientific董事会的提名成员。他拥有宾夕法尼亚大学国际关系学士学位和哥伦比亚大学工商管理硕士学位。


Arthur C. Butcher,is Executive Vice President and Group President, MedSurg and Asia Pacific, a position he has held since May 2022. In this role, he oversees Asia Pacific, as well as Urology, Endoscopy and Neuromodulation businesses. Since joining the Company in 1997, Mr. Butcher has held management roles of increasing responsibility and has deep experience across the Company's divisions, including Executive Vice President and President, Asia Pacific (2020 to 2022), responsible for commercialization of Boston Scientific Corporation full product portfolio across all divisions in the Asia Pacific region; Senior Vice President and President, Endoscopy (2016 to 2020), responsible for developing and bringing to market less invasive devices for treating gastrointestinal and pulmonary conditions; VP & General Manager, Japan Endoscopy (2014 to 2016); VP of Global Marketing, Endoscopy Division (2011 to 2014); and VP of Marketing and New Business Development, Urology & Women's Health (2008 to 2009) and VP of Business Development and Strategic Planning, Urology & Women's Health (2006 to 2008), responsible for leading marketing, strategic planning, and management initiatives within the Endoscopy and Urology businesses. Mr. Butcher is a member of the board of directors of STAAR Surgical Company (since 2024), a public medical device company specializing in implantable lenses, Acotec Scientific Holdings Limited (since 2022), a publicly traded Chinese medical device company, and a member of Global Council for Inclusion. He received an MBA from Columbia University and a BA in international relations from the University of Pennsylvania.
Arthur C. Butcher是Boston Scientific Corporation执行副总裁兼MedSurg和亚太区集团总裁,自2022年5月起担任该职位。在这个职位上,他负责监督亚太地区,以及Boston Scientific Corporation泌尿外科内窥镜检查和神经调节业务。在担任现职之前,Butcher先生于2020年2月至2022年5月担任Boston Scientific Corporation执行副总裁兼亚太区总裁,负责Boston Scientific Corporation在亚太地区所有部门的全部产品组合的商业化。此前,Butcher曾担任Boston Scientific Corporation高级副总裁兼内窥镜总裁,2016年7月至2020年2月担任该职位。在这个职位上,他负责开发用于治疗胃肠道和肺部疾病的侵入性较小的设备并将其推向市场。2014年8月至2016年6月,他还担任日本内窥镜副总裁兼总经理。Butcher先生曾在内窥镜和泌尿外科部门担任过多个营销和战略规划管理职位,包括2011年4月至2014年8月的内窥镜部门全球营销副总裁,以及泌尿外科和女性健康部门新业务发展和战略规划副总裁。自1997年加入Boston Scientific Corporation公司以来,Butcher先生一直担任管理职务,责任越来越大,在各个部门都有丰富的经验。Butcher先生是Boston Scientific Corporation全球包容性理事会的成员,也是中国上市医疗器械公司Acotec Scientific董事会的提名成员。他拥有宾夕法尼亚大学国际关系学士学位和哥伦比亚大学工商管理硕士学位。
Arthur C. Butcher,is Executive Vice President and Group President, MedSurg and Asia Pacific, a position he has held since May 2022. In this role, he oversees Asia Pacific, as well as Urology, Endoscopy and Neuromodulation businesses. Since joining the Company in 1997, Mr. Butcher has held management roles of increasing responsibility and has deep experience across the Company's divisions, including Executive Vice President and President, Asia Pacific (2020 to 2022), responsible for commercialization of Boston Scientific Corporation full product portfolio across all divisions in the Asia Pacific region; Senior Vice President and President, Endoscopy (2016 to 2020), responsible for developing and bringing to market less invasive devices for treating gastrointestinal and pulmonary conditions; VP & General Manager, Japan Endoscopy (2014 to 2016); VP of Global Marketing, Endoscopy Division (2011 to 2014); and VP of Marketing and New Business Development, Urology & Women's Health (2008 to 2009) and VP of Business Development and Strategic Planning, Urology & Women's Health (2006 to 2008), responsible for leading marketing, strategic planning, and management initiatives within the Endoscopy and Urology businesses. Mr. Butcher is a member of the board of directors of STAAR Surgical Company (since 2024), a public medical device company specializing in implantable lenses, Acotec Scientific Holdings Limited (since 2022), a publicly traded Chinese medical device company, and a member of Global Council for Inclusion. He received an MBA from Columbia University and a BA in international relations from the University of Pennsylvania.
Vance R. Brown

Vance R. Brown,是Boston Scientific Corporation的高级副总裁、总法律顾问和公司秘书,自2021年6月起担任该职位。在这个职位上,他在所有业务、地区和职能部门提供全球法律领导,并监督公司的全球合规职能。自2001年加入公司以来,Brown先生担任过越来越多的法律和合规职务,包括2010年至2021年的副总裁、首席公司法律顾问和助理秘书,领导和监督国际法律团队和各种公司法律职能,包括并购、风险投资、公司治理和证券。Brown先生是全球包容理事会的成员。在加入公司之前,他是Skadden、Arps、Slate、Meagher和Flom的律师。他获得了哈佛法学院的博士学位和西安大略大学的学士学位。


Vance R. Brown,is Senior Vice President, General Counsel and Corporate Secretary, a position he has held since June 2021. In this role, he provides global legal leadership across all of businesses, regions and functions and oversees the Company's global compliance function. Since joining the Company in 2001, Mr. Brown has served in a variety of legal and compliance roles of increasing responsibility, including VP, Chief Corporate Counsel and Assistant Secretary from 2010 to 2021, leading and overseeing international legal teams and various corporate legal functions, including mergers and acquisitions, venture capital, corporate governance and securities. Mr. Brown is a member of Global Council for Inclusion. Before joining the Company, he was an attorney with Skadden, Arps, Slate, Meagher and Flom. He received a JD from Harvard Law School and a BA from University of Western Ontario.
Vance R. Brown,是Boston Scientific Corporation的高级副总裁、总法律顾问和公司秘书,自2021年6月起担任该职位。在这个职位上,他在所有业务、地区和职能部门提供全球法律领导,并监督公司的全球合规职能。自2001年加入公司以来,Brown先生担任过越来越多的法律和合规职务,包括2010年至2021年的副总裁、首席公司法律顾问和助理秘书,领导和监督国际法律团队和各种公司法律职能,包括并购、风险投资、公司治理和证券。Brown先生是全球包容理事会的成员。在加入公司之前,他是Skadden、Arps、Slate、Meagher和Flom的律师。他获得了哈佛法学院的博士学位和西安大略大学的学士学位。
Vance R. Brown,is Senior Vice President, General Counsel and Corporate Secretary, a position he has held since June 2021. In this role, he provides global legal leadership across all of businesses, regions and functions and oversees the Company's global compliance function. Since joining the Company in 2001, Mr. Brown has served in a variety of legal and compliance roles of increasing responsibility, including VP, Chief Corporate Counsel and Assistant Secretary from 2010 to 2021, leading and overseeing international legal teams and various corporate legal functions, including mergers and acquisitions, venture capital, corporate governance and securities. Mr. Brown is a member of Global Council for Inclusion. Before joining the Company, he was an attorney with Skadden, Arps, Slate, Meagher and Flom. He received a JD from Harvard Law School and a BA from University of Western Ontario.
Jonathan Monson

Jonathan Monson,他于1999年加入公司,并担任多个职位。Monson先生目前担任公司投资者关系高级副总裁,自2024年3月起担任该职位。在此职位上,他领导公司的投资者关系部门,包括与投资者和分析师的接触。在此之前,Monson先生于2019年7月至2024年3月担任全球财务总监兼首席会计官,负责公司的全球财务总监组织,其中包括公司的会计和财务规划流程。在此之前,Monson先生曾担任财务和会计部门的各种职务,包括2016年至2019年担任公司泌尿业务副总裁兼财务总监,2008年至2016年担任公司会计副总裁。在加入公司之前,他是Arthur Andersen LLP的高级审计师。他持有the College of the Holy Cross的经济学和会计学学士学位,是一名注册会计师。


Jonathan Monson,joined the Company in 1999, and has served in a number of roles of increasing responsibility. Mr. Monson currently serves as the Company's Senior Vice President, Investor Relations, a position he has held since March 2024. In this role, he leads the Company's Investor Relations function, including engagement with investors and analysts. Prior to that, Mr. Monson served as Global Controller and Chief Accounting Officer from July 2019 to March 2024, where he was responsible for the Company's Global Controllership organization, including, among other things, the Company's accounting and financial planning processes. Prior to that, Mr. Monson served in various roles within finance and accounting, including as Vice President and Controller of the Company's Urology business from 2016 to 2019, and Vice President, Corporate Accounting from 2008 to 2016. Prior to joining the Company, he was a senior auditor at Arthur Andersen LLP. Mr. Monson received a BA degree in economics and accounting from the College of the Holy Cross and is a certified public accountant.
Jonathan Monson,他于1999年加入公司,并担任多个职位。Monson先生目前担任公司投资者关系高级副总裁,自2024年3月起担任该职位。在此职位上,他领导公司的投资者关系部门,包括与投资者和分析师的接触。在此之前,Monson先生于2019年7月至2024年3月担任全球财务总监兼首席会计官,负责公司的全球财务总监组织,其中包括公司的会计和财务规划流程。在此之前,Monson先生曾担任财务和会计部门的各种职务,包括2016年至2019年担任公司泌尿业务副总裁兼财务总监,2008年至2016年担任公司会计副总裁。在加入公司之前,他是Arthur Andersen LLP的高级审计师。他持有the College of the Holy Cross的经济学和会计学学士学位,是一名注册会计师。
Jonathan Monson,joined the Company in 1999, and has served in a number of roles of increasing responsibility. Mr. Monson currently serves as the Company's Senior Vice President, Investor Relations, a position he has held since March 2024. In this role, he leads the Company's Investor Relations function, including engagement with investors and analysts. Prior to that, Mr. Monson served as Global Controller and Chief Accounting Officer from July 2019 to March 2024, where he was responsible for the Company's Global Controllership organization, including, among other things, the Company's accounting and financial planning processes. Prior to that, Mr. Monson served in various roles within finance and accounting, including as Vice President and Controller of the Company's Urology business from 2016 to 2019, and Vice President, Corporate Accounting from 2008 to 2016. Prior to joining the Company, he was a senior auditor at Arthur Andersen LLP. Mr. Monson received a BA degree in economics and accounting from the College of the Holy Cross and is a certified public accountant.
Joseph M. Fitzgerald

Joseph M. Fitzgerald是Boston Scientific Corporation执行副总裁兼集团心脏病学总裁,自2022年5月起担任该职位。在这个职位上,他负责开发节律管理技术和创新解决方案,诊断和治疗冠状动脉疾病和结构性心脏疾病,并将其推向市场。他曾于2022年1月至2022年4月担任心脏病学执行副总裁兼总裁,于2020年7月至2022年1月担任介入心脏病学执行副总裁兼总裁,于2014年2月至2020年7月担任心律管理执行副总裁兼总裁,于2011年7月至2014年2月担任心律管理高级副总裁兼总裁。在此之前,他在2010年2月至2011年7月期间担任高级副总裁兼血管内血管总裁,并担任外周干预总裁兼总经理和电生理学总裁。Fitzgerald先生曾在Boston Scientific Corporation神经血管和外周介入业务部门担任过各种管理职务。其中包括许多地区和部门的销售管理任务,直到他担任神经血管业务全球营销副总裁和神经血管业务美国销售副总裁。Fitzgerald先生是Boston Scientific Corporation全球包容性理事会的成员,也是Boston Scientific Corporation EmpowHER员工资源小组的执行发起人。在1990年作为销售代表加入公司之前,Fitzgerald先生曾在Anheuser Busch公司工作,担任过各种销售、营销和培训任务。Fitzgerald先生拥有印第安纳大学商学学士学位和南伊利诺伊大学市场营销和金融专业的工商管理硕士学位。


Joseph M. Fitzgerald,is Executive Vice President and Group President, Cardiology, a position he has held since May 2022. In this role, he oversees development and commercialization of rhythm management technologies and innovative solutions that diagnose and treat coronary artery disease and structural heart disorders. Since joining the Company in 1990 as a sales representative, Mr. Fitzgerald has held a variety of management positions in Neurovascular and Peripheral Interventions businesses, which included numerous regional and divisional sales management assignments up to and including his roles as VP, Global Marketing for the Neurovascular business and VP of U.S. sales for the Neurovascular business. During this time he served as Executive Vice President and President, Cardiology (January 2022 to April 2022), Executive Vice President and President, Interventional Cardiology (June 2020 to January 2022), Executive Vice President and President, Rhythm Management Group (2014 to 2020), Senior Vice President and President, Cardiac Rhythm Management (2011 to 2014), Senior Vice President and President, Endovascular (2008 to 2011) and President and General Manager of Peripheral Interventions and President of Electrophysiology (2005-2008) and Vice President, Marketing & Sales - Neurovascular Division (1998-2005). Mr. Fitzgerald is a member of Global Council for Inclusion and is executive sponsor of EmpowHER employee resource group. He received an MBA from Southern Illinois University with a concentration in marketing and finance and a BS in business from Indiana University.
Joseph M. Fitzgerald是Boston Scientific Corporation执行副总裁兼集团心脏病学总裁,自2022年5月起担任该职位。在这个职位上,他负责开发节律管理技术和创新解决方案,诊断和治疗冠状动脉疾病和结构性心脏疾病,并将其推向市场。他曾于2022年1月至2022年4月担任心脏病学执行副总裁兼总裁,于2020年7月至2022年1月担任介入心脏病学执行副总裁兼总裁,于2014年2月至2020年7月担任心律管理执行副总裁兼总裁,于2011年7月至2014年2月担任心律管理高级副总裁兼总裁。在此之前,他在2010年2月至2011年7月期间担任高级副总裁兼血管内血管总裁,并担任外周干预总裁兼总经理和电生理学总裁。Fitzgerald先生曾在Boston Scientific Corporation神经血管和外周介入业务部门担任过各种管理职务。其中包括许多地区和部门的销售管理任务,直到他担任神经血管业务全球营销副总裁和神经血管业务美国销售副总裁。Fitzgerald先生是Boston Scientific Corporation全球包容性理事会的成员,也是Boston Scientific Corporation EmpowHER员工资源小组的执行发起人。在1990年作为销售代表加入公司之前,Fitzgerald先生曾在Anheuser Busch公司工作,担任过各种销售、营销和培训任务。Fitzgerald先生拥有印第安纳大学商学学士学位和南伊利诺伊大学市场营销和金融专业的工商管理硕士学位。
Joseph M. Fitzgerald,is Executive Vice President and Group President, Cardiology, a position he has held since May 2022. In this role, he oversees development and commercialization of rhythm management technologies and innovative solutions that diagnose and treat coronary artery disease and structural heart disorders. Since joining the Company in 1990 as a sales representative, Mr. Fitzgerald has held a variety of management positions in Neurovascular and Peripheral Interventions businesses, which included numerous regional and divisional sales management assignments up to and including his roles as VP, Global Marketing for the Neurovascular business and VP of U.S. sales for the Neurovascular business. During this time he served as Executive Vice President and President, Cardiology (January 2022 to April 2022), Executive Vice President and President, Interventional Cardiology (June 2020 to January 2022), Executive Vice President and President, Rhythm Management Group (2014 to 2020), Senior Vice President and President, Cardiac Rhythm Management (2011 to 2014), Senior Vice President and President, Endovascular (2008 to 2011) and President and General Manager of Peripheral Interventions and President of Electrophysiology (2005-2008) and Vice President, Marketing & Sales - Neurovascular Division (1998-2005). Mr. Fitzgerald is a member of Global Council for Inclusion and is executive sponsor of EmpowHER employee resource group. He received an MBA from Southern Illinois University with a concentration in marketing and finance and a BS in business from Indiana University.
Wendy Carruthers

Wendy Carruthers是Boston Scientific Corporation人力资源执行副总裁,自2022年2月起担任该职位。在此职位上,她负责监督公司在全球的人力资源活动,包括人力资源运营和服务、总奖励、人才管理、多样性和包容性以及社区参与。在担任现职之前,Carruthers女士从2012年12月至2022年2月担任人力资源高级副总裁,从2012年8月至2012年11月担任临时人力资源主管,并从2011年1月至2012年11月担任Boston Scientific Corporation全球人才管理副总裁。Carruthers女士自2004年以来一直在公司工作,曾担任多个职位,如Boston Scientific Corporation欧洲、中东和非洲地区人力资源副总裁;欧洲人力资源副总裁和欧洲人力资源总监。Carruthers女士是Boston Scientific Corporation全球包容理事会的共同主席。在加入Boston Scientific Corporation公司之前,Carruthers女士是欧洲有线和无线人力资源副总裁。Carruthers女士拥有Salford大学现代语言一级荣誉学士学位,并且是英国特许人事与发展学会的研究员。她是上市牙科制造和营销公司Envista Holdings Corporation、Boston Scientific基金会和大Boston食品银行Emeriti董事会的董事。


Wendy Carruthers,is Boston Scientific Corporation Executive Vice President, Human Resources, a position she has held since February 2022. In this role, she is responsible for overseeing the Company's human resources activities globally, including human resources operations and services, total rewards, talent management, diversity and inclusion and community engagement. Prior to her current role, Ms. Carruthers served as Senior Vice President, Human Resources from December 2012 until February 2022, the Head of Human Resources on an interim basis from August 2012 to November 2012, as well as Boston Scientific Corporation Vice President of Global Talent Management from January 2011 to November 2012. Ms. Carruthers has been with the Company since 2004 and has held various positions such as, Vice President of Human Resources for Boston Scientific Corporation Europe, Middle East and Africa region; Vice President of Human Resources for Europe and Director of Human Resources for Europe. Ms. Carruthers serves as a Co-Chair of Boston Scientific Corporation Global Council for Inclusion. Prior to joining the Company, Ms. Carruthers was Vice President of Human Resources, Europe for Cable & Wireless. Ms. Carruthers holds a B.A. First Class Honors Degree in Modern Languages from the University of Salford and is a Fellow of the Chartered Institute of Personnel and Development. She serves on the board of directors of Envista Holdings Corporation, a publicly traded dental manufacturing and marketing company, the Boston Scientific Foundation, and the Greater Boston Food Bank Emeriti Board.
Wendy Carruthers是Boston Scientific Corporation人力资源执行副总裁,自2022年2月起担任该职位。在此职位上,她负责监督公司在全球的人力资源活动,包括人力资源运营和服务、总奖励、人才管理、多样性和包容性以及社区参与。在担任现职之前,Carruthers女士从2012年12月至2022年2月担任人力资源高级副总裁,从2012年8月至2012年11月担任临时人力资源主管,并从2011年1月至2012年11月担任Boston Scientific Corporation全球人才管理副总裁。Carruthers女士自2004年以来一直在公司工作,曾担任多个职位,如Boston Scientific Corporation欧洲、中东和非洲地区人力资源副总裁;欧洲人力资源副总裁和欧洲人力资源总监。Carruthers女士是Boston Scientific Corporation全球包容理事会的共同主席。在加入Boston Scientific Corporation公司之前,Carruthers女士是欧洲有线和无线人力资源副总裁。Carruthers女士拥有Salford大学现代语言一级荣誉学士学位,并且是英国特许人事与发展学会的研究员。她是上市牙科制造和营销公司Envista Holdings Corporation、Boston Scientific基金会和大Boston食品银行Emeriti董事会的董事。
Wendy Carruthers,is Boston Scientific Corporation Executive Vice President, Human Resources, a position she has held since February 2022. In this role, she is responsible for overseeing the Company's human resources activities globally, including human resources operations and services, total rewards, talent management, diversity and inclusion and community engagement. Prior to her current role, Ms. Carruthers served as Senior Vice President, Human Resources from December 2012 until February 2022, the Head of Human Resources on an interim basis from August 2012 to November 2012, as well as Boston Scientific Corporation Vice President of Global Talent Management from January 2011 to November 2012. Ms. Carruthers has been with the Company since 2004 and has held various positions such as, Vice President of Human Resources for Boston Scientific Corporation Europe, Middle East and Africa region; Vice President of Human Resources for Europe and Director of Human Resources for Europe. Ms. Carruthers serves as a Co-Chair of Boston Scientific Corporation Global Council for Inclusion. Prior to joining the Company, Ms. Carruthers was Vice President of Human Resources, Europe for Cable & Wireless. Ms. Carruthers holds a B.A. First Class Honors Degree in Modern Languages from the University of Salford and is a Fellow of the Chartered Institute of Personnel and Development. She serves on the board of directors of Envista Holdings Corporation, a publicly traded dental manufacturing and marketing company, the Boston Scientific Foundation, and the Greater Boston Food Bank Emeriti Board.